NP G2 044
Alternative Names: DC-05F-01; NP-G2-044Latest Information Update: 22 Jan 2026
At a glance
- Originator Novita Pharmaceuticals; Weill Cornell Medical College
- Developer CR Double-Crane Pharmaceuticals; Novita Pharmaceuticals
- Class Amides; Antineoplastics; Fluorinated hydrocarbons; Furans; Indazoles; Small molecules
- Mechanism of Action Fascin protein inhibitors
-
Orphan Drug Status
Yes - Pancreatic cancer
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Ovarian cancer
- Phase I/II Small cell lung cancer; Solid tumours
Most Recent Events
- 12 Jan 2026 NP G2 044 receives Orphan Drug status for Pancreatic cancer in USA
- 24 Oct 2025 Phase-II/III clinical trials in Ovarian cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in USA (PO) (NCT07109414)
- 24 Oct 2025 Phase-II/III clinical trials in Ovarian cancer (Late-stage disease, Second-line therapy or greater, Monotherapy) in USA (PO) (NCT07109414)